司库奇尤单抗持续改善活动性强直性脊柱炎的症状和体征且保留率高:III期试验MEASURE 2的3年结果
MEASURE 2是一项5年III期随机双盲双模拟平行分组安慰剂对照研究,评估皮下负荷和维持剂量司库奇尤单抗治疗成人活动性强直性脊柱炎的疗效与安全性。第16-156周,司库奇尤单抗150 mg和75 mg的保留率分别为86%和76%;150 mg第156周ASAS 20/40应答率为70.1%/60.9%,第52周为74.2%/57.0%,75 mg略有下降。结论为3年内体征、症状和躯体功能持续改善,保留率高且耐受性良好。
要点
- 司库奇尤单抗150 mg和75 mg第16-156周保留率分别为86%和76%。
- 150 mg第156周ASAS 20/40应答率70.1%/60.9%,第52周为74.2%/57.0%。
- 无论既往是否暴露于抗肿瘤坏死因子药物均观察到临床获益。
核心结论
- 司库奇尤单抗治疗3年持续改善强直性脊柱炎患者的体征、症状和躯体功能,保留率高且耐受性良好,安全性特征良好。
研究设计与样本
- MEASURE 2(NCT01649375)是一项5年III期随机、双盲、双模拟、平行分组、安慰剂对照研究,评估皮下负荷和维持剂量司库奇尤单抗在成人活动性强直性脊柱炎受试者中的疗效、安全性和耐受性。
- 受试者随机接受皮下司库奇尤单抗150 mg、75 mg或安慰剂,于基线、第1、2、3周给药,自第4周起每4周给药一次;第16周时安慰剂组受试者重新随机接受司库奇尤单抗150/75 mg。
主要发现
- 第16-156周保留率高,司库奇尤单抗150 mg和75 mg分别为86%和76%。
- 司库奇尤单抗150 mg第156周ASAS 20/40应答率为70.1%/60.9%,第52周为74.2%/57.0%。
- 司库奇尤单抗75 mg第156周ASAS 20/40应答率为54.3%/37.0%,第52周为62.5%/43.2%,略有下降。
- 其他终点(包括BASDAI、ASDAS-CRP不活动疾病、ASAS 5/6、SF-36躯体成分总结和ASAS部分缓解)均观察到持续改善。
- 无论既往是否暴露于抗肿瘤坏死因子药物均观察到临床获益,安全性特征保持良好并与既往报告一致。
关键数值与推荐
- 第16-156周保留率:司库奇尤单抗150 mg为86%,75 mg为76%。
- 第156周ASAS 20/40应答率:司库奇尤单抗150 mg为70.1%/60.9%,75 mg为54.3%/37.0%。
- 第52周ASAS 20/40应答率:司库奇尤单抗150 mg为74.2%/57.0%,75 mg为62.5%/43.2%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Secukinumab treatment has previously been shown to significantly improve the signs and symptoms of active ankylosing spondylitis (AS), with responses sustained through 2 years. Here, we report the long-term (3 years) efficacy and safety of secukinumab in the MEASURE 2 study. METHODS: MEASURE 2 (NCT01649375) is a 5-year phase III, randomised, double-blind, double-dummy, parallel-group, placebo-controlled study to evaluate the efficacy, safety and tolerability of subcutaneous loading and maintenance dosing of secukinumab in adult subjects with active AS. Subjects were randomised to receive subcutaneous secukinumab 150 mg, 75 mg or placebo at baseline, weeks 1, 2 and 3 and every 4 weeks from week 4. At week 16, placebo-treated subjects were rerandomised to receive secukinumab 150/75 mg. RESULTS: Retention rates were high during weeks 16-156 and were 86% and 76% for secukinumab 150 and 75 mg, respectively. Secukinumab 150 mg provided sustained improvements in the Assessment of Spondyloarthritis International Society ASAS 20/40 response rates at week 156 (70.1%/60.9%) compared with week 52 (74.2%/57.0%); however, there was a slight decrease for secukinumab 75 mg (54.3%/37.0% vs 62.5%/43.2%, respectively). Sustained improvements were observed in all other end points, including Bath Ankylosing Spondylitis Disease Activity Index, AS Disease Activity Score with C reactive protein inactive disease, ASAS 5/6, Short Form-36 Physical Component Summary and ASAS partial remission. Clinical benefits were observed regardless of prior exposure to anti-tumour necrosis factor agents. The safety profile remained favourable and was consistent with previous reports. CONCLUSIONS: This study showed sustained improvement through 3 years in signs, symptoms and physical function in subjects with AS. Retention rates were high and secukinumab was well tolerated, with a favourable safety profile.
引用
- Marzo-Ortega H, Sieper J, Kivitz A, et al. Secukinumab provides sustained improvements in the signs and symptoms of active ankylosing spondylitis with high retention rate: 3-year results from the phase III trial, MEASURE 2. RMD Open. 2017. PMID: 29435364. doi:10.1136/rmdopen-2017-000592
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。